Eisai Executives Warns U.K.'s NICE To Change Approval System
This article was originally published in PharmAsia News
Eisai Deputy President Yutaka Tsuchiya warned the U.K.'s drug-regulating body that if it does not improve its drug-registering process, the Japan-based company would reduce planned investments in the country.
You may also be interested in...
A recent segment of CBS News “60 Minutes” discussing potential health benefits from probiotics was highly criticized by groups including the Consumer Healthcare Products Association, the Council for Responsible Nutrition, the Natural Products Association and the International Probiotics Association.
After a 12-month period that has seen Stada make significant investments in generics, biosimilars and consumer healthcare, CEO Peter Goldschmidt tells Generics Bulletin that the firm does not intend to stop there, as it pursues both organic and inorganic growth opportunities.
Samsung Bioepis is the latest company to stare down a lawsuit from Genentech over Avastin patents in the US. The Korean firm is aiming to be amongst the early biosimilar movers, after the market formed a year ago.